STOCK TITAN

Materialise (NASDAQ: MTLS) posts Q1 profit and exits eyewear unit

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Materialise NV reported first quarter 2026 revenue of 66,276 kEUR, essentially flat year over year, but turned to a net profit of 1,820 kEUR from a loss of 535 kEUR. Adjusted EBIT rose to 2,470 kEUR, a 3.7% margin versus 1.0% a year earlier, and Adjusted EBITDA increased to 8,049 kEUR.

Medical revenue grew 6.7% to 33,165 kEUR, while Software declined slightly and Manufacturing fell 8.1%, though both segments improved profitability. Gross margin expanded to 57.2%. The company ended the quarter with 132,952 kEUR in cash, a 72,826 kEUR net cash position, and positive free cash flow.

Materialise agreed to transfer its eyewear business to its management team, retaining a minority stake and expecting impairment charges in the second quarter of 2026. Despite the Rapidfit and Eyewear divestments, the company reaffirmed its 2026 revenue guidance of 273,000–283,000 kEUR and Adjusted EBIT guidance of 10,000–12,000 kEUR.

Positive

  • None.

Negative

  • None.

Insights

Materialise improved profitability, sharpened its portfolio, and kept 2026 guidance intact.

Materialise delivered flat Q1 2026 revenue at 66,276 kEUR but significantly better earnings, moving from a 535 kEUR loss to a 1,820 kEUR profit. Adjusted EBIT climbed to 2,470 kEUR and Adjusted EBITDA to 8,049 kEUR, helped by tighter cost control and higher gross margin of 57.2%.

Performance varied by segment: Medical revenue increased 6.7% to 33,165 kEUR with strong margins, while Software revenue slipped 1.4% yet nearly doubled segment Adjusted EBITDA. Manufacturing revenue fell 8.1%, but the segment swung from negative to positive Adjusted EBITDA, showing early benefits from operational focus.

The company continued portfolio pruning, following the Rapidfit sale with an agreement to transfer its eyewear business to management, while keeping a minority stake. Management expects related impairment charges in Q2 2026 but maintained full-year 2026 guidance for revenue of 273,000–283,000 kEUR and Adjusted EBIT of 10,000–12,000 kEUR, supported by a net cash position of 72,826 kEUR and ongoing positive free cash flow.

Q1 2026 revenue 66,276 kEUR Total revenue for the three months ended March 31, 2026
Q1 2026 net profit 1,820 kEUR Net profit versus a net loss of 535 kEUR in Q1 2025
Q1 2026 Adjusted EBIT 2,470 kEUR Adjusted EBIT margin 3.7% versus 1.0% in Q1 2025
Q1 2026 Adjusted EBITDA 8,049 kEUR Adjusted EBITDA up from 6,147 kEUR in Q1 2025
Medical segment revenue 33,165 kEUR Q1 2026 Materialise Medical revenue, up 6.7% year over year
Manufacturing segment revenue 23,470 kEUR Q1 2026 Materialise Manufacturing revenue, down 8.1% year over year
Gross margin 57.2% Gross profit as a percentage of revenue in Q1 2026, up from 55.3%
Net cash position 72,826 kEUR Net cash at March 31, 2026, after 132,952 kEUR cash and 60,126 kEUR gross debt
Adjusted EBIT financial
"Adjusted EBIT for the first quarter of 2026 increased to 2,470 kEUR"
Adjusted EBIT is a company’s operating profit before interest and taxes, but cleaned up by removing one-time or unusual items that can obscure ongoing performance. Investors use it like a tidied-up report card — it aims to show the underlying profitability of the business by excluding irregular gains, losses, or costs so comparisons across periods or companies are clearer and more meaningful for valuing operational strength.
Adjusted EBITDA financial
"Adjusted EBITDA for the first quarter of 2026 increased to 8,049 kEUR"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
segment Adjusted EBITDA margin financial
"the segment Adjusted EBITDA margin was 27.8% compared to 29.1%"
A segment adjusted EBITDA margin measures how much profit a specific business unit or division keeps from its sales after removing routine costs like interest, taxes and accounting for depreciation, and after excluding one‑time or unusual items. It’s expressed as a percentage of that segment’s revenue, helping investors compare underlying profitability across parts of a company the way you’d compare the true operating performance of different stores by ignoring temporary expenses or bookkeeping quirks.
net cash position financial
"our net cash position increased by 2,021 kEUR to 72,826 kEUR"
The net cash position is the amount of cash and easily sold assets a company has after subtracting its outstanding debt, essentially “money in the wallet” minus what it owes. Investors care because it shows how easily a company can cover bills, invest in growth, buy back shares, or weather a downturn — stronger net cash usually means lower financial risk and more strategic flexibility, much like a household with savings and little debt.
treasury shares financial
"Materialise had bought back 511,513 own shares for a total amount"
Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.
impairment charges financial
"we expect to recognize impairment charges in the second quarter of 2026"
Impairment charges are one-time accounting write-downs taken when a company decides an asset — like a factory, brand, patent, or investment — is worth less than it was recorded for. Like marking down the price of a damaged item on a store shelf, they reduce reported profits and the asset’s book value; investors watch them because they can signal lasting business problems or change future earnings and balance-sheet strength.
Revenue 66,276 kEUR stable versus 66,379 kEUR in Q1 2025
Net profit 1,820 kEUR from a net loss of 535 kEUR in Q1 2025
Adjusted EBIT 2,470 kEUR margin 3.7% versus 1.0% in Q1 2025
Adjusted EBITDA 8,049 kEUR up from 6,147 kEUR in Q1 2025
Medical segment revenue 33,165 kEUR +6.7% year over year
Guidance

For fiscal year 2026, Materialise reaffirmed revenue guidance of 273,000–283,000 kEUR and Adjusted EBIT guidance of 10,000–12,000 kEUR.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 2026

 

Commission File Number: 001-36515

 

 

Materialise NV

 

 

Technologielaan 15

3001 Leuven

Belgium

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x           Form 40-F ¨

 

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit   Description
     
99.1   Press Release dated May 7, 2026

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

MATERIALISE NV  
     
By: /s/ Brigitte de Vet-Veithen  
Name: Brigitte de Vet-Veithen  
     
  De Vet Management BV  
Title: Chief Executive Officer  

 

Date: May 7, 2026

 

 

 

 

 

Exhibit 99.1 

 

 

Materialise reports first quarter 2026 results

 

Materialise transfers eyewear business to its management team

 

Regulated information1

 

LEUVEN, Belgium--(BUSINESS WIRE)—May 7, 2026 -- Materialise NV (Euronext & NASDAQ:MTLS), a global leader in 3D-printed medical devices and software, and a pioneer in additive manufacturing software and services, today announced its financial results for the first quarter ended March 31, 2026. Additionally, Materialise announced the transfer of its eyewear business to the eyewear management team.

 

Highlights – First Quarter 2026

 

·Total revenue was stable at 66,276 kEUR for the first quarter of 2026 compared to 66,379 kEUR for the corresponding 2025 period.
·Gross profit as a percentage of revenue for the first quarter of 2026 increased to 57.2%, compared to 55.3% for the corresponding 2025 period.
·Adjusted EBIT increased to 2,470 kEUR for the first quarter of 2026 from 646 kEUR for the first quarter of 2025.
·Net result for the first quarter of 2026 was 1,820 kEUR, or 0.03 EUR per diluted share, compared to a net loss of (535) kEUR, or (0.01) EUR per diluted share, for the corresponding 2025 period.
·Driven by recurring positive free cash flow, our net cash position increased by 2,021 kEUR over the quarter to 72,826 kEUR, while 2,308 kEUR was invested in share buybacks, underscoring strong cash generation.

 

CEO Brigitte de Vet-Veithen commented, “In a quarter where elevated geopolitical uncertainty and unfavorable foreign currency exchange movements weighed on our revenue growth, we improved operational profitability across all business segments through operational focus and continued cost control. We closed the quarter with positive operating and free cash flow and a further improved net cash position, reinforcing the strength of our balance sheet and providing us with the flexibility to continue investing in innovation and growth. Following the sale of our Rapidfit business at the end of March of this year, we have now also reached an agreement to transfer our eyewear activities to the business’s management team. We believe these decisive portfolio actions will allow Materialise to further concentrate capital and resources on its core focus areas, while enabling both Rapidfit and Eyewear to operate in a setup that will best support their next phase of growth.”

 

First Quarter 2026 Results

 

Total revenue for the first quarter of 2026 was stable at 66,276 kEUR from 66,379 kEUR for the first quarter of 2025. Adjusted EBIT for the first quarter of 2026 increased to 2,470 kEUR compared to 646 kEUR for the 2025 period. The Adjusted EBIT margin (Adjusted EBIT divided by total revenue) for the first quarter of 2026 was 3.7%, compared to 1.0% for the first quarter of 2025. Adjusted EBITDA for the first quarter of 2026 increased to 8,049 kEUR compared to 6,147 kEUR for the 2025 period.

 

Revenue from our Materialise Medical segment increased 6.7% to 33,165 kEUR for the first quarter of 2026 compared to 31,078 kEUR for the same period in 2025. Segment Adjusted EBITDA increased 2.1% to 9,235 kEUR for the first quarter of 2026 compared to 9,047 kEUR, while the segment Adjusted EBITDA margin was 27.8% compared to 29.1% for the first quarter of 2025.

 

Revenue from our Materialise Software segment decreased 1.4% to 9,641 kEUR for the first quarter of 2026 from 9,775 kEUR for the same quarter last year. Segment Adjusted EBITDA increased 87.4% to 1,123 kEUR from 599 kEUR, while the segment Adjusted EBITDA margin increased to 11.6%, compared to 6.1% for the prior-year period.

 

Revenue from our Materialise Manufacturing segment decreased 8.1% to 23,470 kEUR for the first quarter of 2026 from 25,526 kEUR for the first quarter of 2025. Segment Adjusted EBITDA increased to 281 kEUR compared to (377) kEUR, while the segment Adjusted EBITDA margin increased to 1.2% compared to (1.5)% for the first quarter of 2025.

 

Gross profit increased 3.2% to 37,894 kEUR compared to 36,724 kEUR for the same period last year, while gross profit as a percentage of revenue increased to 57.2% compared to 55.3% for the first quarter of 2025.

 

Research and development (“R&D”), sales and marketing (“S&M”), and general and administrative (“G&A”) expenses remained stable, in the aggregate, at 36,713 kEUR for the first quarter of 2026 from 36,510 kEUR for the first quarter of 2025.

 

Net other operating income was 909 kEUR compared to 360 kEUR for the first quarter of 2025.

 

 

1          The enclosed information constitutes regulated information as defined in the Belgian Royal Decree of 14 November 2007 regarding the duties of issuers of financial instruments which have been admitted for trading on a regulated market.

 

 

 

 

Operating result increased to 2,090 kEUR compared to 574 kEUR for the first quarter of 2025, while net financial result was 392 kEUR, compared to (875) kEUR for the first quarter of 2025.

 

The first quarter of 2026 contained net tax expenses of (662) kEUR, compared to net tax expenses of (234) kEUR in the first quarter of 2025.

 

As a result of the above, net profit for the first quarter of 2026 increased to 1,820 kEUR, compared to a net loss of (535) kEUR for the same period in 2025. Total comprehensive income for the first quarter of 2026, which includes exchange differences on translation of foreign operations, was 2,374 kEUR compared to (30) kEUR for the 2025 period.

 

At March 31, 2026, we had cash and cash equivalents of 132,952 kEUR compared to 133,918 kEUR at December 31, 2025. Gross debt amounted to 60,126 kEUR, compared to 63,113 kEUR at December 31, 2025. As a result, our net cash position increased by 2,021 kEUR to 72,826 kEUR. At the end of the first quarter of 2026 Materialise had bought back 511,513 own shares for a total amount (excluding transaction cost) of 2,308 kEUR (2,722 kUSD) under the previously announced share buy-back program.

 

Cash flow from operating activities for the first quarter of 2026 was 6,914 kEUR. Total cash out from capital expenditures for the first quarter of 2026 amounted to 1,470 kEUR resulting in a positive free cash flow.

 

Net shareholders’ equity at March 31, 2026 was 255,595 kEUR compared to 255,482 kEUR at December 31, 2025.

 

On April 23, 2026, Materialise released its 2025 Annual Report, including its CSRD report, outlining the integration of sustainability into its corporate strategy. With this integrated report we aim at providing transparency on our corporate matters, our financial performance in 2025 and on the initiatives we are taking to make a sustainable difference with additive manufacturing for a better and healthier world. The report is available on our corporate website or can be accessed directly through https://investors.materialise.com/financials/reports.

 

Materialise to transfer eyewear business to its management team

 

Today, Materialise announces it has reached an agreement to transfer its eyewear business to the business’s management team. We believe the transaction aligns with Materialise’s strategy to sharpen its portfolio and to further concentrate capital and resources on its core focus areas, while enabling both Rapidfit and Eyewear to operate in a setup that will best support their next phase of growth. Materialise will retain a minority stake in the newly formed eyewear company, reflecting its continued confidence in the business. All employees currently supporting the eyewear business will transition to the new company formed in connection with the transfer. The financial terms of the transaction were not publicly disclosed, and we expect to recognize impairment charges in the second quarter of 2026 related to the transaction.

 

2026 Guidance

 

Mrs. de Vet-Veithen concluded, “As previously communicated in our guidance issued in February, we expect macro-economic and geopolitical uncertainty to persist throughout fiscal year 2026. Nevertheless, we continue to have confidence in the strength and resilience of our underlying business fundamentals. The strategic repositioning initiatives and targeted investments across our three business segments are expected to progressively support operational performance and profitable growth. Notwithstanding the anticipated impact of the divestments of Rapidfit and Eyewear, we reaffirm our full-year revenue guidance for fiscal year 2026 in the range of 273,000 to 283,000 kEUR. In addition, we are maintaining our Adjusted EBIT guidance for fiscal year 2026 of 10,000 to 12,000 kEUR, reflecting our continued focus on execution discipline, cost management, and capital allocation.”

 

Non-IFRS Measures

 

Materialise uses EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA as supplemental financial measures of its financial performance, including for purposes of monitoring compliance with financial covenants, supporting discussions with financing institutions, and meeting reporting requirements to our banks. EBIT is calculated as net profit plus income taxes, financial expenses (less financial income) and shares of profit or loss in a joint venture. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of profit or loss in a joint venture and depreciation and amortization. Adjusted EBIT and Adjusted EBITDA are determined by adding to EBIT and EBITDA, respectively (i) share-based compensation expenses, (ii) acquisition expenses related to business combinations or divestiture-related expenses, (iii) impairments and revaluation of fair value due to business combinations and (iv) costs incurred in relation to corporate initiatives, restructurings or reorganizations that are of a non-recurring nature. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of financing decisions and, in the case of EBITDA and Adjusted EBITDA, long term investment, rather than the performance of the company’s day-to-day operations. The company also uses segment Adjusted EBITDA and segment Adjusted EBITDA margin to evaluate the performance of its three business segments. As compared to net profit, these measures are limited in that they do not reflect the cash requirements necessary to service interest or principal payments on the company’s indebtedness and, in the case of EBITDA and Adjusted EBITDA, these measures are further limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company’s business, or the changes associated with impairments. Management evaluates such items through other financial measures such as financial expenses, capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company’s ability to grow or as a valuation measurement. The company’s calculation of EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company’s presentation of EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.

 

 

 

 

Exchange Rate

 

This document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.1498, the reference rate of the European Central Bank on March 31, 2026.

 

Conference Call and Webcast

 

Materialise will hold a conference call and simultaneous webcast to discuss its financial results for the first quarter of 2026 on Thursday, May 7, 2026, at 8:30 a.m. ET/2:30 p.m. CET. Company participants on the call will include Brigitte de Vet-Veithen, Chief Executive Officer and Koen Berges, Chief Financial Officer. A question-and-answer session will follow management’s remarks.

 

To access the call by phone, please click the link below at least 15 minutes prior to the scheduled start time and you will be provided with dial-in details. Participants can choose to dial in or receive a call to connect to Materialise’s conference call.

 

·https://register-conf.media-server.com/register/BI7e584baacee14013bd0ffd0406fb9ccd

 

The conference call will also be broadcast live over the Internet with an accompanying slide presentation, which can be accessed on the company’s website at http://investors.materialise.com. The webcast of the conference call will be archived on the company's website for one year.

 

About Materialise

 

Materialise NV incorporates more than three decades of 3D printing experience into a range of software solutions and 3D printing services that empower sustainable 3D printing applications. Our open, secure, and innovative end-to-end solutions enable flexible industrial manufacturing and mass personalization in various industries — including healthcare, automotive, aerospace, eyewear, art and design, wearables, and consumer goods. Headquartered in Belgium and with branches worldwide, Materialise NV combines the largest group of software developers in the industry with one of the world's largest and most complete 3D printing facilities. For additional information, please visit: www.materialise.com.

 

Cautionary Statement on Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business, including statements concerning, among other things, our estimates for the current fiscal year’s revenue and Adjusted EBIT, our results of operations, cash needs, capital expenditures, expenses, financial condition, liquidity, prospects, divestitures, growth and strategies (including how our business, results of operations and financial condition could be impacted by the current armed geopolitical conflicts around the world and governmental responses thereto, inflation, increased labor, energy and materials costs), policy changes resulting from the U.S. presidential administration, changes in tariffs and trade restrictions, and the trends and competition that may affect the markets, industry or us. Such statements are subject to known and unknown uncertainties and risks. When used in this press release, the words “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “will,” “may,” “could,” “might,” “aim,” “should,” and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. These expectations, beliefs and projections are expressed in good faith and the company believes there is a reasonable basis for them. However, the company cannot offer any assurance that our expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All of the forward-looking statements are subject to risks and uncertainties that may cause the company's actual results to differ materially from our expectations, including risk factors described in the company's most recent annual report on Form 20-F filed with the U.S. Securities and Exchange Commission. There are a number of risks and uncertainties that could cause the company's actual results to differ materially from the forward-looking statements contained in this press release.

 

The company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

 

 

 

 

Consolidated income statements (Unaudited)

 

   for the three months ended
March 31,
 
In '000  2026   2026   2025 
   U.S.$       
Revenue   76,204    66,276    66,379 
Cost of Sales   (32,634)   (28,383)   (29,654)
Gross Profit   43,570    37,894    36,724 
Gross profit as % of revenue   57.2%   57.2%   55.3%
                
Research and development expenses   (13,671)   (11,890)   (11,414)
Sales and marketing expenses   (17,748)   (15,435)   (15,071)
General and administrative expenses   (10,793)   (9,387)   (10,025)
Net other operating income (expenses)   1,045    909    360 
Operating (loss) profit   2,403    2,090    574 
                
Financial expenses   (804)   (700)   (2,772)
Financial income   1,256    1,092    1,897 
(Loss) profit before taxes   2,855    2,483    (301)
                
Income Taxes   (762)   (662)   (234)
Net (loss) profit for the period   2,093    1,820    (535)
Net (loss) profit attributable to:               
The owners of the parent   2,093    1,820    (533)
Non-controlling interest   -    -    (2)
                
Earning per share attributable to owners of the parent               
Basic   0.04    0.03    (0.01)
Diluted   0.04    0.03    (0.01)
                
Weighted average basic shares outstanding   58,865    58,865    59,067 
Weighted average diluted shares outstanding   58,865    58,865    59,067 

 

 

 

 

Consolidated statements of comprehensive income (Unaudited)

 

   for the three months ended
March 31,
 
In 000€  2026   2026   2025 
   U.S.$       
Net profit (loss) for the period   2,093    1,820    (535)
Other comprehensive income               
Recycling               
Exchange difference on translation of foreign operations   637    554    505 
Non-recycling               
Fair value adjustments through OCI   -    -    - 
Other comprehensive income (loss), net of taxes   637    554    505 
Total comprehensive income (loss) for the year, net of taxes   2,730    2,374    (30)
Total comprehensive income (loss) attributable to:               
The owners of the parent   2,733    2,377    (32)
Non-controlling interests   (3)   (3)   1 

 

 

 

 

Consolidated statement of financial position (Unaudited)

 

   As of
March 31,
   As of
December 31,
 
In 000€  2026   2025 
Assets          
Non-current assets          
Goodwill   43,171    43,161 
Intangible assets   24,589    25,639 
Property, plant & equipment   111,635    112,854 
Right-of-Use assets   5,774    5,429 
Deferred tax assets   3,834    3,971 
Other non-current assets   5,249    5,983 
Total non-current assets   194,253    197,038 
Current assets          
Inventories   16,753    14,904 
Trade receivables   55,462    54,938 
Other current assets   14,924    15,533 
Cash and cash equivalents   132,952    133,918 
Assets held for sale   4,183    4,314 
Total current assets   224,274    223,607 
Total assets   418,527    420,646 

 

 

 

 

   As of
March 31,
   As of
December 31,
 
In 000€  2026   2025 
Equity and liabilities          
Equity          
Share capital   4,487    4,487 
Share premium   203,895    203,895 
Treasury Shares   (2,308)   - 
Retained earnings and other reserves   49,604    47,180 
Equity attributable to the owners of the parent   255,678    255,562 
Non-controlling interest   (83)   (80)
Total equity   255,595    255,482 
Non-current liabilities          
Loans & borrowings   47,190    49,726 
Lease liabilities   3,299    3,063 
Deferred tax liabilities   2,566    2,660 
Deferred income   16,845    17,344 
Other non-current liabilities   321    486 
Total non-current liabilities   70,221    73,280 
Current liabilities          
Loans & borrowings   6,824    7,759 
Lease liabilities   2,813    2,565 
Trade payables   19,783    20,125 
Tax payables   869    748 
Deferred income   44,165    43,523 
Other current liabilities   18,088    16,362 
Liabilities held for sale   168    802 
Total current liabilities   92,711    91,884 
Total equity and liabilities   418,527    420,646 

 

 

 

 

Consolidated statement of cash flows (Unaudited)

 

   for the three months ended
March 31,
 
In 000€  2026   2025 
Operating activities          
Net (loss) profit for the period   1,820    (535)
Non-cash and operational adjustments   5,820    6,994 
Depreciation of property plant & equipment   3,999    3,854 
Amortization of intangible assets   1,651    1,631 
Share-based payment expense   56    72 
Loss (gain) on disposal of intangible assets and property, plant & equipment   (54)   21 
Government grants   (112)   - 
Movement in provisions   (156)   18 
Movement reserve for bad debt and slow moving inventory   196    243 
Financial income   (1,111)   (1,834)
Financial expense   722    2,763 
Impact of foreign currencies   (34)   (2)
(Deferred) income taxes   663    228 
Working capital adjustments   (1,693)   3,763 
Decrease (increase) in trade receivables and other receivables   50    4,487 
Decrease (increase) in inventories and contracts in progress   (1,933)   948 
Increase (decrease) in deferred revenue   71    1,868 
Increase (decrease) in trade payables and other payables   119    (3,539)
Income tax paid   326    (1,140)
Interest received   640    631 
Net cash flow from operating activities   6,914    9,713 

 

 

 

 

   for the three months ended
March 31,
 
In 000€  2026   2025 
Investing activities          
Purchase of property, plant & equipment   (969)   (1,400)
Purchase of intangible assets   (501)   (432)
Proceeds from the sale of property, plant & equipment & intangible assets (net)   70    75 
Capital government grants received   229    - 
Net cash flow used in investing activities   (1,171)   (1,757)
Financing activities          
Repayment of loans & borrowings   (3,459)   (4,472)
Repayment of leases   (751)   (815)
Interest paid   (473)   (235)
Other financial income (expense)   19    (310)
Repurchase of treasury shares   (2,317)   - 
Net cash flow from (used in) financing activities   (6,982)   (5,832)
Net increase/(decrease) of cash & cash equivalents   (1,238)   2,123 
Cash & Cash equivalents at the beginning of the year   133,918    102,304 
Exchange rate differences on cash & cash equivalents   329    (247)
Cash & cash equivalents at end of the period   133,009    104,180 

 

 

 

 

Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited)

 

   for the three months ended
March 31,
 
In 000€  2026   2025 
Net profit (loss) for the period   1,820    (535)
Income taxes   662    234 
Financial expenses   700    2,772 
Financial income   (1,092)   (1,897)
Depreciation and amortization   5,578    5,501 
EBITDA   7,669    6,075 
Share-based compensation expense (1)   56    72 
Restructuring and corporate initiatives (2)   257    - 
Impairments (3)   67    - 
Adjusted EBITDA   8,049    6,147 

 

(1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees.

(2) Non-recurring costs related to corporate initiatives, restructurings or reorganizations

(3) Impairments represent the impairment of tangible and intangible assets of RapidFit NV resulting from the asset transfer to its management.

 

Reconciliation of Net Profit (Loss) to EBIT and Adjusted EBIT (Unaudited)

 

   for the three months ended
March 31,
 
In 000€  2026   2025 
Net profit (loss) for the period   1,820    (535)
Income taxes   662    234 
Financial expenses   700    2,772 
Financial income   (1,092)   (1,897)
EBIT   2,090    574 
Share-based compensation expense (1)   56    72 
Restructuring and corporate initiatives (2)   257    - 
Impairments (3)   67    - 
Adjusted EBIT   2,470    646 

 

(1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees.

(2) Non-recurring costs related to corporate initiatives, restructurings or reorganizations

(3) Impairments represent the impairment of tangible and intangible assets of RapidFit NV resulting from the asset transfer to its management.  

 

 

 

 

Segment P&L (Unaudited)

 

In 000€  Materialise
Medical
   Materialise
Software
   Materialise
Manufacturing
   Total
segments
   Unallocated (1)   Consolidated 
For the three months ended March 31, 2026                              
Revenues   33,165    9,641    23,470    66,276    0    66,276 
Segment (adj) EBITDA   9,235    1,123    281    10,638    (2,589)   8,049 
Segment (adj) EBITDA %   27.8%   11.6%   1.2%   16.1%        12.1%
For the three months ended March 31, 2025                              
Revenues   31,078    9,775    25,526    66,379    0    66,379 
Segment (adj) EBITDA   9,047    599    (377)   9,269    (3,122)   6,147 
Segment (adj) EBITDA %   29.1%   6.1%   -1.5%   14.0%        9.3%

 

(1) Unallocated segment adjusted EBITDA consists of corporate research and development and corporate other operating income (expense), and the added share-based compensation expenses, acquisition expenses related to business combinations or divestiture-related expenses, impairments and revaluation of fair value of business combinations and non-recurring costs related to corporate initiatives, restructurings and reorganizations that are included in Adjusted EBITDA and that are not allocated to the reporting segments .

 

 

 

 

Reconciliation of Net Profit (Loss) to Segment adjusted EBITDA (Unaudited)

 

   for the three months ended
March 31,
 
In 000€  2026   2025 
Net profit (loss) for the period   1,820    (535)
Income taxes   662    234 
Financial expenses   700    2,772 
Financial income   (1,092)   (1,897)
Operating (loss) profit   2,090    574 
Depreciation and amortization   5,578    5,501 
Corporate research and development   878    1,030 
Corporate headquarter costs   2,998    2,852 
Other operating income (expense)   (974)   (688)
Impairments (1)   67    - 
Segment adjusted EBITDA   10,638    9,269 

 

(1) Impairments represent the impairment of tangible and intangible assets of RapidFit NV resulting from the asset transfer to its management.                

 

 

 

FAQ

How did Materialise (MTLS) perform financially in Q1 2026?

Materialise posted stable Q1 2026 revenue of 66,276 kEUR and turned a prior-year loss into a net profit of 1,820 kEUR. Gross margin improved to 57.2%, Adjusted EBIT rose to 2,470 kEUR, and Adjusted EBITDA increased to 8,049 kEUR, reflecting better operational efficiency.

What were the segment results for Materialise (MTLS) in Q1 2026?

Materialise Medical revenue grew 6.7% to 33,165 kEUR, with segment Adjusted EBITDA of 9,235 kEUR. Software revenue slipped 1.4% to 9,641 kEUR but nearly doubled segment Adjusted EBITDA to 1,123 kEUR. Manufacturing revenue fell 8.1% to 23,470 kEUR, yet segment Adjusted EBITDA turned positive at 281 kEUR.

What strategic portfolio changes did Materialise (MTLS) announce?

Materialise sold its Rapidfit business at the end of March and agreed to transfer its eyewear business to that unit’s management team. The company will retain a minority stake in the new eyewear company, expects impairment charges in Q2 2026, and aims to focus capital on core areas.

What is Materialise’s (MTLS) cash and debt position after Q1 2026?

At March 31, 2026, Materialise held 132,952 kEUR in cash and cash equivalents and gross debt of 60,126 kEUR. This resulted in a net cash position of 72,826 kEUR. The company also generated 6,914 kEUR of operating cash flow and positive free cash flow during the quarter.

Did Materialise (MTLS) change its 2026 financial guidance?

Materialise reaffirmed its full-year 2026 revenue guidance in the range of 273,000 to 283,000 kEUR and its Adjusted EBIT guidance of 10,000 to 12,000 kEUR. This guidance is maintained despite anticipated impacts from the Rapidfit and Eyewear divestments and ongoing macroeconomic uncertainty.

What share buyback activity did Materialise (MTLS) report?

By the end of Q1 2026, Materialise had repurchased 511,513 own shares under its share buyback program. The total purchase amount was 2,308 kEUR, or 2,722 kUSD, excluding transaction costs. These treasury shares are reflected as a 2,308 kEUR reduction within equity on the balance sheet.

Filing Exhibits & Attachments

1 document